# US 2016/0243144 A1 · Fixed dose combination formulations of rifaximin and lactulose

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0243144 A1
- Document ID: US20160243144A1
- Status: Published application
- Kind: A1
- Application number: 15/049,293
- Filed: 2016-02-22
- Published: 2016-08-25
- Earliest claimed: 2015-02-21
- Assignees: Oakdene Holdings LLC
- Applicants: Oakdene Holdings LLC
- Inventors: James Garegnani; Aman Trehan
- Web page: https://patentgrep.com/patent/US20160243144A1

## CPC

- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 9/10: Dispersions; Emulsions
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A fixed dose combination formulation of rifaximin or a pharmaceutically acceptable salt thereof and lactulose is provided. The formulation is used for the prevention, treatment, or maintaining remission of HE; reducing the recurrence of HE episodes; reducing the recurrence of HE episodes in a patient refractory or non-responsive to rifaximin or lactulose monotherapy; or reducing the frequency of hospital visit.

## Claims

### Claim 1

An oral formulation comprising fixed dose combination of rifaximin or a pharmaceutically acceptable salt thereof and lactulose for preventing, treating, or maintaining remission of hepatic encephalopathy.

### Claim 2 (depends on 1)

The oral formulation of claim 1, wherein the daily dose of rifaximin or a pharmaceutically acceptable salt thereof is about 25 mg to about 6000 mg.

### Claim 3 (depends on 1)

The oral formulation of claim 1, wherein the daily dose of lactulose or a pharmaceutically acceptable salt thereof is about 10 mg to about 20 gm.

### Claim 4 (depends on 1)

The oral formulation of claim 1, wherein the dose of rifaximin or a pharmaceutically acceptable salt thereof is greater than or equal to the dose of lactulose.

### Claim 5 (depends on 1)

The oral formulation of claim 1, wherein the combined weight of rifaximin and lactulose is less than about 80% of the weight of rifaximin or lactulose alone required to achieve same therapeutic effect in patient to which the formulation is administered.

### Claim 6 (depends on 1)

The oral formulation of claim 1, wherein the ratio of amount of rifaximin or a pharmaceutically acceptable salt thereof to lactulose ranges from about 0.05:1 to about 50:1.

### Claim 7 (depends on 1)

The oral formulation of claim 1, wherein the ratio of amount of rifaximin or a pharmaceutically acceptable salt thereof to lactulose ranges from about 1:1 to about 50:1.

### Claim 8 (depends on 1)

The oral formulation of claim 1, wherein the formulation comprises from about 30% w/w to about 70% w/w of rifaximin or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The oral formulation of claim 1, wherein the formulation comprises from about 20% w/w to about 80% w/w of lactulose.

### Claim 10 (depends on 1)

The oral formulation of claim 1, wherein the formulation is in the form of an oral suspension.

### Claim 11 (depends on 1)

The oral formulation of claim 1, wherein the formulation is in the form of a sachet.

### Claim 12 (depends on 1)

The oral formulation of claim 1, wherein the formulation is in the form of a tablet.

### Claim 13 (depends on 1)

The oral formulation of claim 1, wherein the formulation is in the form of a capsule.

### Claim 14

An oral formulation comprising fixed dose combination of rifaximin or a pharmaceutically acceptable salt thereof and lactulose for treating, preventing or maintaining remission of hepatic encephalopathy, wherein once-a-day administration of said suspension provides steady state blood levels of rifaximin or lactulose that are comparable to steady state blood levels of rifaximin or lactulose achieved with simultaneous administration of separate dosage forms containing the same amount of rifaximin and lactulose.

### Claim 15 (depends on 1)

A method of treating, preventing or maintaining remission of hepatic encephalopathy in a patient in need thereof comprising administering the oral formulation of claim 1 to such patient.

### Claim 16 (depends on 15)

The method of claim 15, wherein said method comprises administration of said formulation for greater than one or more of 365 days, 730 days, or 1095 days.

### Claim 17 (depends on 1)

A method of reducing the frequency of hospitalization visit by a patient suffering from hepatic encephalopathy, comprising administering the oral formulation of claim 1 to said patient.

### Claim 18 (depends on 1)

A method of reducing the recurrence of hepatic encephalopathy episodes in a patient in need thereof comprising administering the oral formulation of claim 1 to said patient.

### Claim 19 (depends on 1)

A method of reducing the recurrence of hepatic encephalopathy episodes in a patient refractory or non-responsive to rifaximin or lactulose monotherapy comprising administering the oral formulation of claim 1 to said patient.

### Claim 20 (depends on 1)

A method of reducing at least one side effect of rifaximin and/or lactulose therapy in patient suffering from hepatic encephalopathy, said side effects being selected from peripheral edema, nausea, dizziness, fatigue, ascites, dehydration, electrolyte disturbances, abdominal cramping, and combinations of said side effects, comprising administering the oral formulation of claim 1 to said patient.
